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STELLINGEN
Behorend bij het proefschrift
Myocardial reperfusion in STEMI and the role  
of the antithrombotic/antiplatelet therapy
1. The electrocardiographic assessment of myocardial reperfusion remains a prognostic marker of 
clinical outcomes even in the modern era of STEMI treatment - This thesis
2. Pre-hospital ticagrelor administration may be beneficial in STEMI patients being transported to 
hospitals for primary PCI, particularly when longer transfer delays can be expected - This thesis
3. In patients with STEMI, the “patient delay” must be minimized as much as possible for improving 
myocardial reperfusion - This thesis
4. Diabetes mellitus remains an independent predictor of poor myocardial reperfusion even in 
STEMI patients treated with early antithrombotic treatment and despite fast cath-lab transfer 
time - This thesis
5. Heparin remains the anticoagulant of choice in patient with STEMI undergoing primary PCI  
- This thesis
6. An high-risk subset of STEMI patients, as identified by higher levels of NT-proBNP upon 
presentation, may derive particular benefit from early GPIs treatment - This thesis
7. Limiting DAPT duration to six months in event-free STEMI patients is safe, and may be 
considered in patients with high bleeding risk or if clinically mandated - This thesis
8. Medicine is a science of uncertainty and an art of probability - William Osler
9. The scientist is not a person who gives the right answers, he is one who asks the right questions 
- Claude Levi-Strauss
10. Pro veritate adversa diligere (for love of truth, I willingly go to confront difficulties)  
- Carlo Maria Martini
